Striatal pleiotrophin overexpression provides functional and morphological neuroprotection in the 6-hydroxydopamine model

Molecular Therapy

Volumn 20, Issue 3, 2012, Pages 544-554

  Gombash, Sara E ^a,b,c   Lipton, Jack W ^c   Collier, Timothy J ^c   Madhavan, Lalitha ^a,b   Steece Collier, Kathy ^c   Cole Strauss, Allyson ^c   Terpstra, Brian T ^a,b   Spieles Engemann, Anne L ^a,b   Daley, Brian F ^b   Wohlgenant, Susan L ^c   Thompson, Valerie B ^a,b   Manfredsson, Fredric P ^c   Mandel, Ronald J ^d   Sortwell, Caryl E ^c  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF CINCINNATI   (United States)

^c MICHIGAN STATE UNIVERSITY   (United States)

^d UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; OXIDOPAMINE; PLEIOTROPHIN; TYROSINE 3 MONOOXYGENASE;

ADENO ASSOCIATED VIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL DENSITY; CONTROLLED STUDY; DEVELOPMENTAL STAGE; FUNCTIONAL STATUS; IMMUNOREACTIVITY; MALE; NEURITE; NEUROPROTECTION; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PSEUDOTYPING; RAT; STRIATE CORTEX; SUBSTANTIA NIGRA PARS COMPACTA; VIRUS RECOMBINANT;

ADENO-ASSOCIATED VIRUS; PARKINSONIA;

EID: 84857787470     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2011.216     Document Type: Article

References (50)

1. Dorsey, ER, Constantinescu, R, Thompson, JP, Biglan, KM, Holloway, RG, Kieburtz, K et al. (2007). Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology 68: 384-386. (Pubitemid 46184217)
2. Tomac, A, Lindqvist, E, Lin, LF, Ogren, SO, Young, D, Hoffer, BJ et al. (1995). Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo. Nature 373: 335-339.
3. Björklund, A, Kirik, D, Rosenblad, C, Georgievska, B, Lundberg, C and Mandel, RJ (2000). Towards a neuroprotective gene therapy for Parkinson's disease: use of adenovirus, AAV and lentivirus vectors for gene transfer of GDNF to the nigrostriatal system in the rat Parkinson model. Brain Res 886: 82-98.
4. Kirik, D, Rosenblad, C, Bjorklund, A and Mandel, RJ (2000). Long-term rAAV-mediated gene transfer of GDNF in the rat Parkinson's model: intrastriatal but not intranigral transduction promotes functional regeneration in the lesioned nigrostriatal system. J Neurosci 20: 4686-4700. (Pubitemid 30396634)
5. Kirik, D, Georgievska, B, Rosenblad, C and Björklund, A (2001). Delayed infusion of GDNF promotes recovery of motor function in the partial lesion model of Parkinson's disease. Eur J Neurosci 13: 1589-1599. (Pubitemid 32423344)
6. Kordower, JH, Herzog, CD, Dass, B, Bakay, RA, Stansell, J 3rd, Gasmi, M et al. (2006). Delivery of neurturin by AAV2 (CERE-120)-mediated gene transfer provides structural and functional neuroprotection and neurorestoration in MPTP-treated monkeys. Ann Neurol 60: 706-715. (Pubitemid 46048488)
7. Fjord-Larsen, L, Johansen, JL, Kusk, P, Tornøe, J, Grønborg, M, Rosenblad, C et al. (2005). Efficient in vivo protection of nigral dopaminergic neurons by lentiviral gene transfer of a modified Neurturin construct. Exp Neurol 195: 49-60. (Pubitemid 41116813)
8. Mandel, RJ, Spratt, SK, Snyder, RO and Leff, SE (1997). Midbrain injection of recombinant adeno-associated virus encoding rat glial cell line-derived neurotrophic factor protects nigral neurons in a progressive 6-hydroxydopamine-induced degeneration model of Parkinson's disease in rats. Proc Natl Acad Sci USA 94: 14083-14088.
9. Kells, AP, Eberling, J, Su, X, Pivirotto, P, Bringas, J, Hadaczek, P et al. (2010). Regeneration of the MPTP-lesioned dopaminergic system after convection-enhanced delivery of AAV2-GDNF. J Neurosci 30: 9567-9577.
10. Nutt, JG, Burchiel, KJ, Comella, CL, Jankovic, J, Lang, AE, Laws, ER Jr et al.; ICV GDNF Study Group. Implanted intracerebroventricular. Glial cell line-derived neurotrophic factor. (2003). Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD. Neurology 60: 69-73. (Pubitemid 36070646)
11. Lang, AE, Gill, S, Patel, NK, Lozano, A, Nutt, JG, Penn, R et al. (2006). Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. Ann Neurol 59: 459-466. (Pubitemid 43358066)
12. Marks, WJ Jr, Bartus, RT, Siffert, J, Davis, CS, Lozano, A, Boulis, N et al. (2010). Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial. Lancet Neurol 9: 1164-1172.
13. Rauvala, H and Pihlaskari, R (1987). Isolation and some characteristics of an adhesive factor of brain that enhances neurite outgrowth in central neurons. J Biol Chem 262: 16625-16635.
14. Vanderwinden, JM, Mailleux, P, Schiffmann, SN and Vanderhaeghen, JJ (1992). Cellular distribution of the new growth factor pleiotrophin (HB-GAM) mRNA in developing and adult rat tissues. Anat Embryol 186: 387-406.
15. Hida, H, Jung, CG, Wu, CZ, Kim, HJ, Kodama, Y, Masuda, T et al. (2003). Pleiotrophin exhibits a trophic effect on survival of dopaminergic neurons in vitro. Eur J Neurosci 17: 2127-2134. (Pubitemid 36713973)
16. Marchionini, DM, Lehrmann, E, Chu, Y, He, B, Sortwell, CE, Becker, KG et al. (2007). Role of heparin binding growth factors in nigrostriatal dopamine system development and Parkinson's disease. Brain Res 1147: 77-88. (Pubitemid 46584663)
17. Taravini, IR, Chertoff, M, Cafferata, EG, Courty, J, Murer, MG, Pitossi, FJ et al. (2011). Pleiotrophin over-expression provides trophic support to dopaminergic neurons in parkinsonian rats. Mol Neurodegener 6: 40.
18. Ferrario, JE, Rojas-Mayorquín, AE, Saldaña-Ortega, M, Salum, C, Gomes, MZ, Hunot, S et al. (2008). Pleiotrophin receptor RPTP-δ/αexpression is up-regulated by L-DOPA in striatal medium spiny neurons of parkinsonian rats. J Neurochem 107: 443-452.
19. Ferrario, JE, Taravini, IR, Mourlevat, S, Stefano, A, Delfino, MA, Raisman-Vozari, R et al. (2004). Differential gene expression induced by chronic levodopa treatment in the striatum of rats with lesions of the nigrostriatal system. J Neurochem 90: 1348-1358. (Pubitemid 39223639)
20. Kinnunen, T, Raulo, E, Nolo, R, Maccarana, M, Lindahl, U and Rauvala, H (1996). Neurite outgrowth in brain neurons induced by heparin-binding growth-associated molecule (HB-GAM) depends on the specific interaction of HB-GAM with heparan sulfate at the cell surface. J Biol Chem 271: 2243-2248.
21. Reimsnider, S, Manfredsson, FP, Muzyczka, N and Mandel, RJ (2007). Time course of transgene expression after intrastriatal pseudotyped rAAV2/1, rAAV2/2, rAAV2/5, and rAAV2/8 transduction in the rat. Mol Ther 15: 1504-1511. (Pubitemid 47103062)
22. Burger, C, Gorbatyuk, OS, Velardo, MJ, Peden, CS, Williams, P, Zolotukhin, S et al. (2004). Recombinant AAV viral vectors pseudotyped with viral capsids from serotypes 1, 2, and 5 display differential efficiency and cell tropism after delivery to different regions of the central nervous system. Mol Ther 10: 302-317. (Pubitemid 39117875)
23. Spieles-Engemann, AL, Behbehani, MM, Collier, TJ, Wohlgenant, SL, Steece-Collier, K, Paumier, K et al. (2010). Stimulation of the rat subthalamic nucleus is neuroprotective following significant nigral dopamine neuron loss. Neurobiol Dis 39: 105-115.
24. Collier, TJ and Sortwell, CE (1999). Therapeutic potential of nerve growth factors in Parkinson's disease. Drugs Aging 14: 261-287. (Pubitemid 29195344)
25. Kordower, JH and Sortwell, CE (2000). Neuropathology of fetal nigra transplants for Parkinson's disease. Prog Brain Res 127: 333-344. (Pubitemid 35461266)
26. Rosenblad, C, Kirik, D, Devaux, B, Moffat, B, Phillips, HS and Björklund, A (1999). Protection and regeneration of nigral dopaminergic neurons by neurturin or GDNF in a partial lesion model of Parkinson's disease after administration into the striatum or the lateral ventricle. Eur J Neurosci 11: 1554-1566. (Pubitemid 29192230)
27. Rosenblad, C, Kirik, D and Björklund, A (2000). Sequential administration of GDNF into the substantia nigra and striatum promotes dopamine neuron survival and axonal sprouting but not striatal reinnervation or functional recovery in the partial 6-OHDA lesion model. Exp Neurol 161: 503-516. (Pubitemid 30137010)
28. Wang, L, Muramatsu, S, Lu, Y, Ikeguchi, K, Fujimoto, K, Okada, T et al. (2002). Delayed delivery of AAV-GDNF prevents nigral neurodegeneration and promotes functional recovery in a rat model of Parkinson's disease. Gene Ther 9: 381-389. (Pubitemid 34414036)
29. Meng, K, Rodriguez-Peña, A, Dimitrov, T, Chen, W, Yamin, M, Noda, M et al. (2000). Pleiotrophin signals increased tyrosine phosphorylation of α-catenin through inactivation of the intrinsic catalytic activity of the receptor-type protein tyrosine phosphatase ?. Proc Natl Acad Sci USA 97: 2603-2608. (Pubitemid 30159217)
30. Pariser, H, Ezquerra, L, Herradon, G, Perez-Pinera, P and Deuel, TF (2005). Fyn is a downstream target of the pleiotrophin/receptor protein tyrosine phosphatase-signaling pathway: regulation of tyrosine phosphorylation of Fyn by pleiotrophin. Biochem Biophys Res Commun 332: 664-669. (Pubitemid 40745166)
31. Pariser, H, Perez-Pinera, P, Ezquerra, L, Herradon, G and Deuel, TF (2005). Pleiotrophin stimulates tyrosine phosphorylation of-adducin through inactivation of the transmembrane receptor protein tyrosine phosphatase ?. Biochem Biophys Res Commun 335: 232-239. (Pubitemid 41350785)
32. Perez-Pinera, P, Alcantara, S, Dimitrov, T, Vega, JA and Deuel, TF (2006). Pleiotrophin disrupts calcium-dependent homophilic cell-cell adhesion and initiates an epithelialmesenchymal transition. Proc Natl Acad Sci USA 103: 17795-17800. (Pubitemid 44852239)
33. Kinnunen, A, Kinnunen, T, Kaksonen, M, Nolo, R, Panula, P and Rauvala, H (1998). N-syndecan and HB-GAM (heparin-binding growth-associated molecule) associate with early axonal tracts in the rat brain. Eur J Neurosci 10: 635-648. (Pubitemid 28325486)
34. Kinnunen, T, Kaksonen, M, Saarinen, J, Kalkkinen, N, Peng, HB and Rauvala, H (1998). Cortactin-Src kinase signaling pathway is involved in N-syndecan-dependent neurite outgrowth. J Biol Chem 273: 10702-10708. (Pubitemid 28227685)
35. Herradón, G and Ezquerra, L (2009). Blocking receptor protein tyrosine phosphatase ?: a potential therapeutic strategy for Parkinson's disease. Curr Med Chem 16: 3322-3329.
36. Yang, J, Teng, Q, Garrity-Moses, ME, McClelland, S 3rd, Federici, T, Carlton, E et al. (2007). Reversible unilateral nigrostriatal pathway inhibition induced through expression of adenovirus-mediated clostridial light chain gene in the substantia nigra. Neuromolecular Med 9: 276-284. (Pubitemid 350129703)
37. Manfredsson, FP, Tumer, N, Erdos, B, Landa, T, Broxson, CS, Sullivan, LF et al. (2009). Nigrostriatal rAAV-mediated GDNF overexpression induces robust weight loss in a rat model of age-related obesity. Mol Ther 17: 980-991.
38. Georgievska, B, Kirik, D and Björklund, A (2002). Aberrant sprouting and downregulation of tyrosine hydroxylase in lesioned nigrostriatal dopamine neurons induced by long-lasting overexpression of glial cell line derived neurotrophic factor in the striatum by lentiviral gene transfer. Exp Neurol 177: 461-474. (Pubitemid 35366135)
39. Rosenblad, C, Georgievska, B and Kirik, D (2003). Long-term striatal overexpression of GDNF selectively downregulates tyrosine hydroxylase in the intact nigrostriatal dopamine system. Eur J Neurosci 17: 260-270. (Pubitemid 36459505)
40. Sajadi, A, Bauer, M, Thöny, B and Aebischer, P (2005). Long-term glial cell line-derived neurotrophic factor overexpression in the intact nigrostriatal system in rats leads to a decrease of dopamine and increase of tetrahydrobiopterin production. J Neurochem 93: 1482-1486. (Pubitemid 40853271)
41. Emborg, ME, Moirano, J, Raschke, J, Bondarenko, V, Zufferey, R, Peng, S et al. (2009). Response of aged parkinsonian monkeys to in vivo gene transfer of GDNF. Neurobiol Dis 36: 303-311.
42. Manfredsson, FP, Okun, MS and Mandel, RJ (2009). Gene therapy for neurological disorders: challenges and future prospects for the use of growth factors for the treatment of Parkinson's disease. Curr Gene Ther 9: 375-388.
43. Ciesielska, A, Mittermeyer, G, Hadaczek, P, Kells, AP, Forsayeth, J and Bankiewicz, KS (2011). Anterograde axonal transport of AAV2-GDNF in rat basal ganglia. Mol Ther 19: 922-927.
44. Hida, H, Masuda, T, Sato, T, Kim, TS, Misumi, S and Nishino, H (2007). Pleiotrophin promotes functional recovery after neural transplantation in rats. Neuroreport 18: 179-183.
45. Piltonen, M, Bespalov, MM, Ervasti, D, Matilainen, T, Sidorova, YA, Rauvala, H et al. (2009). Heparin-binding determinants of GDNF reduce its tissue distribution but are beneficial for the protection of nigral dopaminergic neurons. Exp Neurol 219: 499-506.
46. Manfredsson, FP, Burger, C, Sullivan, LF, Muzyczka, N, Lewin, AS and Mandel, RJ (2007). rAAV-mediated nigral human parkin over-expression partially ameliorates motor deficits via enhanced dopamine neurotransmission in a rat model of Parkinson's disease. Exp Neurol 207: 289-301. (Pubitemid 47429661)
47. Zolotukhin, S, Potter, M, Zolotukhin, I, Sakai, Y, Loiler, S, Fraites, TJ Jr et al. (2002). Production and purification of serotype 1, 2, and 5 recombinant adeno-associated viral vectors. Methods 28: 158-167. (Pubitemid 35341079)
48. Burger, C, Nguyen, FN, Deng, J and Mandel, RJ (2005). Systemic mannitol-induced hyperosmolality amplifies rAAV2-mediated striatal transduction to a greater extent than local co-infusion. Mol Ther 11: 327-331.
49. Kirik, D, Rosenblad, C and Björklund, A (1998). Characterization of behavioral and neurodegenerative changes following partial lesions of the nigrostriatal dopamine system induced by intrastriatal 6-hydroxydopamine in the rat. Exp Neurol 152: 259-277. (Pubitemid 28419264)
50. Schallert, T (2006). Behavioral tests for preclinical intervention assessment. NeuroRx 3: 497-504. (Pubitemid 44443020)